Navigation Links
Valensa Expands Astaxanthin Extraction Capacity
Date:2/14/2008

Growing Demand for High-Quality Finished Product that Meets Regulatory & Health Issues and New Strategic Alliance Create Conditions for Expansion

ORLANDO, Fla., Feb. 14 /PRNewswire/ -- Valensa International announced today that it has increased its capacity for the extraction of Haematococcus pluvialis for the manufacture of finished all-natural astaxanthin. The move was made in light of recently growing demand for a high-quality astaxanthin in North America, Asia and Europe that is both pesticide-free and allergen-free - two conditions that are only possible with select raw material sources and extraction facilities. In addition to market demand, a recently formed Strategic Alliance with Cyanotech Corporation (Kona, HI), where Valensa provides extraction services of raw material provided by Cyanotech, will require increased capacity to facilitate orderly growth of supply for the market and increased uptake of Valensa's own ZANTHIN(R) natural astaxanthin brand. The capacity expansion will be approximately 20% and will be achieved primarily through manufacturing efficiencies and de-bottlenecking its facilities in Eustis, Florida, USA. The expansion will include new facilities for screening biomass against the presence of pesticides. Astaxanthin products extracted at Valensa's Eustis facility will be certified pesticide- and allergen-free.

According to Dr. Rudi Moerck, President of Valensa, high-quality astaxanthin biomass and strict quality control in manufacturing are the two key elements for creating a finished astaxanthin product that meets or exceeds the quality and regulatory requirements of world markets. "There is growing interest and excitement about the potential of astaxanthin - the world's most potent antioxidant with clinical trial data indicating support in areas such as eye health, neurological health, immune support, inflammation reduction and skin health. Recently, the demand for a high-quality, pesticide-free source of the product has outstripped supply. The Strategic Alliance that we have formed with Cyanotech Corporation and our move to increase extraction capacity will help meet market requirements for this growing demand," he said. "Valensa has provided extraction services to Cyanotech for some time now and we were impressed by their biomass purity and pesticide-free profile," he said. "Our company has previously qualified a number of astaxanthin biomass sources, but product purity and overall product integrity led us to choose Cyanotech as our principal algae biomass supplier." Valensa's ZANTHIN(R) natural astaxanthin product has been marketed in the United States for over a decade and was the first astaxanthin extract to have Novel Foods approval in the European Union in July 2004. "These approvals require a pesticide-free, solvent-free and allergen-free astaxanthin. By qualifying our suppliers and screening our raw materials, through the use of supercritical carbon dioxide extraction technology and through our superior quality management, we are uniquely positioned to deliver the astaxanthin products required by world markets," said Dr. Moerck.

For further information, contact:

Dr. Rudi Moerck, President

Voice: 352-357-2004

Fax: 352-483-2095

http://www.valensa.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Valensa International
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Progen Expands Drug Development Pipeline Through Acquisition of CellGate
2. Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand
3. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
4. PPD Expands Global Central Lab Services into China
5. The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent
6. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
7. Ventria Expands Team and Hires Kansan as Director of Bioprocessing Operations
8. Symmetry Medical Expands Board of Directors
9. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
10. Observant LLC Expands Senior Management Team
11. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... (PRWEB) , ... April 20, 2017 , ... Parallel6™ ... clinical trials worldwide, announced today that they were named one of the 2017 ... covers the latest developments in the pharmaceutical industry. , “We take pride in honoring ...
(Date:4/20/2017)... For today, Stock-Callers.com redirects investors, attention to Biotechnology, ... research aimed at treating diseases and medical conditions. Under evaluation ... (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), and ZIOPHARM Oncology ... complimentary research reports on these stocks now at: ... http://stock-callers.com/registration Biostage ...
(Date:4/19/2017)... ... April 18, 2017 , ... Optofluidics today announced that ... after the company changed focus to making analytical tools for biopharmaceutical quality control. ... technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart and David Erickson ...
(Date:4/19/2017)... ... April 19, 2017 , ... As part of ... accessible to novices as well as experienced users, attendees will gain a better ... screening tests. , Hemostasis testing quality is determined by preanalytical variables which ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):